Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Acknowledgment of Support
This activity is supported by an educational grant from Amgen, Inc.
Cancer Summaries and Commentaries®: Updates from the Summer Meetings on the Treatment of Acute Lymphoblastic Leukemia
Release Date: September 30, 2021
Expiration Date: September 30, 2022
This online activity is designed to update clinicians on data presented during the 2021 Annual Meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Participation in this activity will help to facilitate critical assessment and clinical integration of new evidence, when appropriate. The activity reviews 6 abstracts from the 2021 ASCO and EHA meetings that focus on acute lymphoblastic leukemia (ALL). For each abstract, a text summary of key clinical data is accompanied by perspectives from expert thought leaders, who provide insights into how these findings may be applied to clinical practice to improve patient care.
Acknowledgement of SupportThis activity is supported by an educational grant from Amgen, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
These activities are intended for medical oncologists, hematologists, and other oncology health care professionals interested in the treatment of patients with acute lymphoblastic leukemia (ALL). Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals are also invited to attend.
Upon successful completion of this activity, you should be better prepared to
- Discuss key efficacy and safety findings from pivotal trials evaluating therapies for acute lymphoblastic leukemia (ALL), including monoclonal antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T-cell therapies
- Outline proactive strategies to promptly recognize and manage treatment-related toxicities in patients who receive ALL treatment
- Evaluate the clinical implications of emerging data sets in the context of evolving treatment paradigms in ALL
Faculty, Staff, and Planners’ DisclosuresThe staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
Chief, Division of Leukemia
Department of Medical Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Disclosures: Grant/Research Support: AbbVie, Blueprint Medicines, GlycoMimetics, Novartis; Consultant: AbbVie, Agios Pharmaceuticals, Amgen Biotechnology, Autolus Therapeutics, Blueprint Medicines, Forty Seven Inc, GlycoMimetics, Incyte Corp, Jazz Pharmaceuticals, Kite Pharma, Novartis, Pfizer, Servier Pharmaceuticals, Takeda Pharmaceutical Co.
Department of Malignant Hematology
H. Lee Moffitt Cancer Center
Associate Professor of Oncologic Sciences
University of South Florida
Disclosures: Grant/Research Support: Jazz Pharmaceuticals, Kite/Gilead, Servier Pharmaceuticals; Consultant: Adaptive Biotechnologies, Amgen Biotechnology, AstraZeneca, BeiGene, Celgene/Bristol Myers Squibb, Century Therapeutics, Kite/Gilead, Novartis, Pfizer, Precision Biosciences.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.